Methotrexate therapy in non-cancer diseases;Les utilisations non cancerologiques du methotrexate

Presse Medicale

Volumn 25, Issue 39, 1996, Pages 1929-1934

  Brion, N ^a   Paule, B ^b  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; ANTIASTHMATIC AGENT; ANTIRHEUMATIC AGENT; DERMATOLOGICAL AGENT;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; AUTOIMMUNITY; CROHN DISEASE; DRUG EFFICACY; DRUG THERAPY; DRUG TOLERANCE; ECTOPIC PREGNANCY; HUMAN; POLYARTHRITIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; ADULT; AGED; CHILD; DRUG CONTRAINDICATION; JUVENILE RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, RHEUMATOID; ASTHMA; CHILD; DERMATOLOGIC AGENTS; DRUG TOLERANCE; HUMANS; METHOTREXATE; PSORIASIS;

EID: 0030583794     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increase adenosine release at inflammed sites diminishes leucocytes accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92:2675-82.
2. Van de Putte LBA, Van Riel PLCM. Do diseases modifying anti rheumatic drugs actually modify disease course in rheumatoid arthritis? Clin Immunother 1994; 1:319-22.
3. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis: indications, contreindications, efficacy and safety. Ann Intern Med 1987; 107:358-66.
4. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second lines drugs in rheumatoid arthritis. Results of two meta analyses. Arthritis Rheum 1990; 33:1449-61.
5. Felson DT, Anderson JJ, Meenan RF. The rheumatoid arthritis: a meta analysis of published clinicals trials. Arthritis Rheum 1992; 35:1117-25.
6. Fries JF, Willians CA, Ramey et al. The relative toxicity of diseases modifying anti rheumatic drugs. Arthritis Rheum 1993; 36:297-306.
7. Ahern MJ, Chandran G. Category III Symptom-modifying anti rheumatic drugs: a comparative review. Clin Immunother 1995; 3:196-217.
8. Wolfe F, Hauley DJ, Cathey MA. Termination of slow acting anti rheumatic therapy in rheumatoid arthritis: a 14 year prospective evaluation of 1017 consecutive starts. J Rheum 1990; 117:994-1002.
9. Marklan A, Faulds D. Methotrexate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in rheumatoid arthritis and other immuno regulatory disorders. Clin Immunother 1994; 1:217-44.
10. Girgis L, Conaghan PG, Brooks P. Disease modifying anti rheumatic drugs including methotrexate, sulfasalazine, gold, antimalarials and penicillamine. Curr Opin Rhumatol 1994; 6:252-61.
11. Weinblatt ME, Weissman BN, Holdsworth DE et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84 months update. Arthritis Rheum 1992; 35:138-44.
12. O'dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with metrotrexate alone, sulfasalazine, hydroxychloroquine or a combination of all three medications. N Engl J Med 1996; 334:1287-91.
13. Tugwell P, Pincus T, Youm D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333:137-41.
14. Weinblatt ME, Polisson R, Blotner DS et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Arthritis Rheum 1993; 36:613-16.
15. Giannini H, Brewer EJ, Kuzmina N et al. Methotrexate in resistant juvenile rheumatoid arthritis, results of the USA-USSR double blind placebo controlled trial. N Engl J Med 1992; 326:1043-9.
16. Lally EV, HO GR Jr. A review of methotrexate therapy in Reiter syndrome. Semin Arthritis Rheum 1985; XV: 139-45.
17. Guss S, Portnoy J. Methotrexate treatment of severe Asthma in children. Pediatrics 1992; 89:635-9.
18. Stempel DA, Lammert J, Mullarkey MF. Use of Methotrexate in the treatment of steroid dependent adolescent asthmatics. Ann Allergy 1991; 67:346-8.
19. Mullarkey MF, Blumenstein BA, Andrade P, Bailey GA, Olason I, Welzel CE. Methotrexate in the treatment of corticodependent Asthma. N Engl J Med 1988; 318:603-7.
20. Shiner RJ, Numm AJ, Chuny KF, Gedder DM. Randomized, double blind, placebo controlled trial of Methotrexate in steroid dependent Asthma. Lancet 1990; 336:137-40.
21. Erzurum SC, Leff JA, Cochran JE et al. Lack of benefit of Methotrexate in severe steroid dependent. Asthma. Ann Intern Med 1991; 114:353-60.
22. Taylor DR, Flannery EM, Herbisson GP. Methotrexate in the management of severe steroid dependent asthma. N Z Med J 1993; 106:409-11.
23. Willians REA. Workshop of the research Unit of the Royal College of Physicians of London. Guidelines for management of patients with psoriasis. Br Med J 1991; 303:829-45.
24. Dyer PD, Vaughan TR, Weber RW. Methotrexate in the treatment of steroid dependent Asthma. J Allergy Clin Immunol 1991; 88:208-12.
25. Metzer AI, Bohan A, Goldberg LS, Bluestone R, Pearson CM. Polymyositis and dermatomyosits: combined methotrexte and corticosteroids therapy. Ann Intern Med 1974; 81:182-98.
26. Van den Hoogen FHJ, Boerbooms AMT, Swaak AJG, Rasker Jj, Van Lier HJJ, Van de Putte LBA. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 weeks randomized double-blind trial, followed by a 24 weeks observation trial. Br J Rheum 1996; 35:364-72.
27. Ormerod AD. Urticaria: recognition causes and treatment. Drugs 1994; 48: 717-30.
28. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn' disease. N Engl J Med 1995; 332:292-7.
29. Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low dose weekly methotrexate. Gastroenterology 1991; 101:1332-8.
30. Kaplan MM, Knox TA. Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 1991; 86:546-52.
31. Knox TA, Kaplan MM, Gelfard JA, Wolff SM. Methotrexate treatment of idiopathic granulomatosis hepatitis. Ann Intern Med 1995; 122:592-5.
32. Schnabel A, Gross WL. Low dose methotrexate in rheumatic diseases efficacy, side effects and risk factors for side effects. Semin Arthritis Rheum 1994; 23:310-17.
33. Bardin PG, Fraenkel DJ, Beasley RW. Methotrexate in asthma. A safety perspective. Drug Saf 1993; 9:151-5.
34. Sherby WJ, Polisson RP, Cadwell DS, Rice JR, Pitersky DS, Allen NB. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am Med J 1988; 85:771-4.
35. Bannwarth B, Labat L, Morid Y, Schaewerke T. Methotrexate in rheumatoid arthritis. Drugs 1994; 47:25-50.
36. Kremer JM, Alarcon GS, Furst DE et al. Methotrexate for rheumatoid arthritis: suggested guideliness for monitoring liver in toxicity. Arthritis Rheum 1994; 37:316-28.
37. Vallerand H, Cossart C, Milosevic D, Lavaud F, Leone J. Fatal pneumocystis pneumonia in asthmatic patient treated with methotrexate. Lancet 1992; 340:1551.